Organization

Geron Corporation

About

Geron is a late-stage clinical biopharmaceutical company focused on developing and possibly commercializing a first-in-class telomerase inhibitor, Imetelstat, which is essentially an experimental drug targeting a hallmark of cancer. The commitment to improve and extend patients' lives by targeting telomerase and changing the course of these diseases is highlighted by the company's two ongoing Phase 3 clinical trials.

Overview

Founded 1990
Type Public
Location Menlo Park, California, USA

Stock

GERN $2.31 -6.48% $(0.16)

Latest News

Marathon Digital, Coinbase Global And Some Other Big Stocks Moving Higher In Today's Pre-Market Session Sep 27, 2022 Benzinga U.S. stock futures traded higher this morning after recording losses in the previous session. Here are some big stocks moving higher in today’s pre-market trading...
Why Kiora Pharmaceuticals Is Trading Lower By Around 22%; Here Are 26 Stocks Moving Premarket Sep 27, 2022 Benzinga Gainers 9 Meters Biopharma, Inc. (NASDAQ: NMTR) rose 31.4% to $0.2720 in pre-market trading after the company disclosed final results from Phase 2 VIBRANT study,...
H.B. Fuller, Lennar And Some Other Big Stocks Moving Higher In Today's Pre-Market Session Sep 22, 2022 Benzinga U.S. stock futures traded slightly higher this morning after recording losses in the previous session. Here are some big stocks moving higher in today’s pre-market...
4 Penny Stocks To Watch For September 2022 Sep 01, 2022 PennyStocks Penny stocks for your September watch list. The post 4 Penny Stocks To Watch For September 2022 appeared first on Penny Stocks to Buy, Picks,...
Why Geron's Shares Rose 14.78% on Wednesday Aug 31, 2022 The Motley Fool The company said it expects to submit a new drug application for its lead candidate early next year.